Tidal Trust II YieldMax BABA Option Income Strategy ETF (ARCA: BABO)

에 대한 최신 뉴스 Tidal Trust II YieldMax BABA Option Income Strategy ETF (ARCA:BABO)

Tidal Trust II YieldMax BABA Option Income Strategy ETF

YieldMax BABA Option Income Strategy ETF

Broad U.S. Equity ETFs

ETFs

AAPL

BABA

BABO

BDRY

SOCL

SURI

WCBR

미국 시장은 1월 31일 종료된 강력한 일주일 동안 많은 것들을 소화해야 했다. 여러 ETF가 연이은 시장 변동성에도 불구하고 두드러진 성과를 보였고, 특히 기술 및 채권 같은 부문에서 주목할 만한 상승세를 보였다. 이번 요약에서 지난주 주요 시장 동향을 자세히 살펴보고 이 기간 동안 상승한 ETF 5종목을 확인해 보자.

지난주 시장 변동성과 거시적 변화 속에도 대폭 상승한 ETF 5종목은?

This one business day extension is to accommodate the settlement and tendering of shares of AspenTech common stock that may be sold due to the S&amp;P MidCap 400 index change.
S&amp;P Global previously announced that AspenTech will be replaced in the index effective prior to the opening of trading on March 11, 2025.

News

AZPN

Emerson Extends Expiration Of Its Tender Offer To Acquire Aspen Technology Shares Not Already Owned To 5:00 P.M. Eastern Time On March 11, 2025

Emerson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EMR#NYSE">EMR</a>) today announced that it has extended the expiration of its tender offer to acquire all outstanding shares of common stock of Aspen Technology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZPN#NASDAQ">AZPN</a>) ("AspenTech") not already owned by Emerson to 5:00 p.m. Eastern Time on March 11, 2025. This one business day extension is to accommodate the settlement and tendering of shares of AspenTech common stock that may be sold due to the S&amp;P MidCap 400 index change. S&amp;P Global previously announced that AspenTech will be replaced in the index effective prior to the opening of trading on March 11, 2025.

Government

Regulations

Emerson Extends AspenTech Tender Offer by One Day to Align With S&P Index Change

Guidance

DSGN

Design Therapeutics Expects Cash And Equivalents Of $245.5M As Of December 31, 2024, To Fund Its Planned Operating Expenses Into 2029

General

TETAA

Telesat And QEST Quantenelektronische Systeme Sign Development Contract For Telesat Lightspeed Aero Flat Panel Antenna

Design Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DSGN#NASDAQ">DSGN</a>) reported quarterly losses of $(0.24) per share which beat the analyst consensus estimate of $(0.28) by 14.29 percent. This is a 14.29 percent decrease over losses of $(0.21) per share from the same period last year.

Earnings

Earnings Beats

Design Therapeutics Q4 2024 GAAP EPS $(0.24) Beats $(0.28) Estimate

GDS Holdings Limited ("GDS Holdings", "GDS" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GDS#NASDAQ">GDS</a>, HKEX: 9698))), a leading developer and operator of high-performance data centers in China, today announced that it has entered into definitive agreements to monetize, on a net basis, a 70% equity interest in certain of its data centers, at an implied enterprise value ("EV") to EBITDA multiple of around 13 times. In a first of a kind transaction, GDS is selling a 100% equity interest in certain data center project companies to a private REIT ("P-REIT"), which is a special purpose equity scheme involving the issue of an Asset Backed Security ("ABS"). The ABS is 70% subscribed by top tier institutional investors in China, led by China Life Insurance Company Limited ("China Life"), whilst GDS subscribes for the remaining 30% and retains the rights for on-going operation of the underlying data centers. The ABS will be listed on the Shanghai Stock Exchange as a standardized security product. The P-REIT structure is specifically designed to facilitate an eventual injection of the ABS into a public REIT vehicle ("C-REIT") when qualified.
The total EV for the transaction is up to approximately RMB 2.9 billion. The total equity consideration is up to approximately RMB 1.7 billion, or RMB 1.2 billion net of the 30% reinvestment by GDS in the ABS. GDS will receive net cash proceeds of approximately RMB 500 million at closing. The remaining net cash proceeds of approximately RMB 700 million will be paid when certain milestones are met related to the ramp-up of the underlying data centers. GDS will deconsolidate the data center project companies including existing debt and other net liabilities of around RMB 1.2 billion at closing.

Asset Sales

GDS Sells 70% Stake in Data Centers to China Life-Led Group in $400M Deal, Plans Future Public REIT Listing

RGNX

REGENXBIO Plans To Present New Interim Biomarker Data From Phase I/II Portion Of AFFINITY DUCHENNE Trial Of RGX-202 At 2025 MDA Clinical & Scientific Conference

Management

FXNC

First National Corporation Appoints Brad Schwartz As President And CFO

NLSP

NLS Pharmaceutics Issues Shareholder Update: Merger Progress, Pipeline Growth, And 18-Month Financial Runway Detailed

&nbsp;<a href="http://www.nlspharma.com/">NLS Pharmaceutics Ltd.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NLSP#NASDAQ">NLSP</a>), a Swiss clinical-stage biopharmaceutical company focused on developing innovative therapies for central nervous system (CNS) disorders, today issued a letter to its shareholders.
<a href="https://mma.prnewswire.com/media/2637716/NLS_Pharmaceutics_Logo.html"><img src="https://mma.prnewswire.com/media/2637716/NLS_Pharmaceutics_Logo.jpg" alt="NLS Pharmaceutics Logo" /></a>
Dear Shareholders,
We are thrilled to share the significant progress and strategic milestones NLS Pharmaceutics has achieved, positioning our company for a transformative future in the biotechnology sector.
Strategic Merger with Kadimastem
In November 2024, we announced a definitive merger agreement with <a href="http://www.kadimastem.com/">Kadimastem Ltd.</a>&nbsp;(TASE: KDST) ("Kadimastem"), a clinical-stage cell therapy company specializing in "off-the-shelf" allogeneic cell products for neurodegenerative diseases and diabetes. This merger aims to create a Nasdaq-traded biotechnology company with a robust portfolio of advanced therapies. Both companies' boards of directors have unanimously approved the transaction, with Kadimastem's shareholders recently voting in favor and NLS major shareholders holding approximately 40% of NLSs' common shares having signed support letters for the NLS shareholders' meeting to be convened soon. We currently anticipate closing the merger in the second quarter of 2025, pending effectiveness of NLSs' pending registration statement filed with the Securities and Exchange Commission ("SEC"), Nasdaq approval, NLSs' shareholders' approval and customary closing conditions.&nbsp;
Regulatory Filings and Approvals
We filed a Registration Statement on Form F-4 and subsequent amendment with the SEC, detailing the proposed merger with Kadimastem. This filing is a necessary step toward finalizing the merger and creating a combined entity focused on innovative therapies.&nbsp;In addition, we have submitted an application to list the merged company on Nasdaq under the name of "NucelX Ltd.", with the future ticker of NCEL.
Advancements in Diabetes Treatment
In collaboration with iTolerance Inc., Kadimastem has successfully completed a pre-Investigational New Drug ("pre-IND") meeting with the U.S. Food and Drug Administration ("FDA") for iTOL-102, a potential breakthrough therapy for Type 1 Diabetes. This innovative approach combines Kadimastem's IsletRx cells with iTolerance's immunomodulator, aiming to cure Type 1 Diabetes without the need for lifelong immune suppression.&nbsp;
The diabetes treatment landscape has experienced significant growth, underscored by notable mergers and acquisitions. For instance, Novo Nordisk's acquisition of Inversago Pharma for up to $1.075 billion highlights the strategic emphasis on developing novel therapies for obesity, diabetes, and related metabolic disorders. Similarly, Roche's $2.7 billion acquisition of Carmot Therapeutics reflects their concerted effort to expand into the diabetes and obesity markets. Additionally, Sana Biotechnology has made significant advancements in the diabetes space, with early clinical data suggesting their hypo immune platform could enable insulin production without immunosuppression, positioning them as a potential leader in developing transformative treatments for type 1 diabetes. We believe that these developments underscore the sector's robust growth and the immense potential it holds for innovative treatments.&nbsp;
Furthermore, we are expanding our diabetes treatment strategies beyond GLP-1 therapies. By integrating complementary approaches, we aim to address the multifaceted challenges of diabetes management, including neuroinflammation and metabolic resilience.&nbsp;
Advancements in Neurodegenerative Disease Treatment
Post-merger, we plan to prepare and initiate a Phase IIa multi-site clinical trial of AstroRx&#xAE;, Kadimastem's product candidate for Amyotrophic Lateral Sclerosis (ALS). This trial is slated to commence following the merger's completion, marking significant progress in our neurodegenerative disease treatment pipeline.&nbsp;
Experienced International Leadership Team&nbsp;
We believe that Kadimastem contributes to the merger with its experienced international leadership team and board of directors, and with the teams prior experience developing medicine from the laboratory to the market.&nbsp;For example,&nbsp;Rebif&#xAE;, a blockbuster drug invented by Professor Michel Revel, Chief Scientist at Kadimastem, in his capacity as a scientific investigator at the world-renowned Weizmann Institute of Science, was acquired by Merck Serono. In addition, Ronen Twito, Kadimastem's Executive Chairman and Chief Executive Officer, brings extensive experience working in the U.S. capital market and M&amp;A international market.
Advancements in DOXA R&amp;D Programs
Our promising Dual Orexin Receptor Agonist ("DOXA") platform has made significant strides. The development of AEX-41 and AEX-2 compounds showcases our dedication to addressing unmet needs in sleep-wake disorders. Preliminary studies have yielded promising results, reinforcing our confidence in these compounds' potential to transform patient care.
Additional Pipeline Expansion and Research Initiatives
Our commitment to addressing critical health challenges remains steadfast:
<ul>
<li>Fentanyl Dependence Treatment: We have launched a preclinical program evaluating Mazindol ER as a treatment for fentanyl dependence, aiming to offer a non-opioid alternative in combating the opioid crisis.</li>
<li>Advancing Scientific&nbsp;Research: Our recent submissions to and upcoming poster presentation at the American Society of Clinical Psychopharmacology's 2025 Annual Meeting highlight our commitment to innovative therapeutic strategies and groundbreaking research.</li>
</ul>
Financial Resilience and Growth
We have fortified our financial foundation through strategic initiatives:
Nasdaq &amp; Strong Financial Position
<ul>
<li>We carry zero long-term debt, a rarity among biopharmaceutical companies. This strong financial position provides us with flexibility to execute our strategic goals without financial constraints.</li>
<li>We raised approximately $4.2 million pursuant to private placements in October and December 2024, at a premium to market price. We currently believe that the amounts raised in these private placements has extended our operational runway to approximately 18 months.</li>
<li>This financial stability empowers us to accelerate clinical development, pursue strategic partnerships, and advance our innovative pipeline with confidence.</li>
</ul>
Looking Ahead
The momentum generated by these developments underscores our commitment to delivering life-changing therapies. We aim to capitalize on emerging opportunities within the dynamic biotechnology landscape, driving NLS Pharmaceutics toward a future of unparalleled success.
As we embark on this exciting new chapter, we remain laser-focused on:
<ul>
<li>Building an international, strong, well-balanced pipeline and top-notch biotechnology company</li>
<li>Delivering life-changing therapies for patients worldwide</li>
<li>Expanding our pipeline through innovation &amp; strategic collaborations</li>
<li>Maximizing shareholder value by maintaining a strong financial position</li>
</ul>
We extend our deepest gratitude to our shareholders, partners, and supporters for your trust and commitment. Together, we are building a future of unparalleled success for NLS Pharmaceutics.
Sincerely,
Alex Zwyer Chief Executive Officer &nbsp;

NLS Pharmaceutics Merger With Kadimastem Aims to Create Nasdaq-Traded Biotech Powerhouse With Therapies, Highlights Diabetes, ALS, and Opioid Treatment Advances, Signals Strong Growth Ahead With Clean Balance Sheet

All future vehicles under Geely's Galaxy brand will be equipped with G-Pilot, including the recently launched Galaxy E8 sedan.

ECARX's Skyland Pro Intelligent Driving Solution Will Be Integrated Into Geely's G-Pilot Unified Intelligent Driving System

ATEX

Anterix Launches Its AnterixAccelerator Initiative With Investment Of Up To $250M

Leveraging its differentiated commercial infrastructure, NeoGenomics expects to grow incremental topline revenue with contributions from the acquired business while operational consolidation efforts and synergies are expected to yield substantial annual cost reductions, which will be accretive to AEBITDA starting in 2026.

Health Care

NeoGenomics Acquired Pathline, Strengthening The Company's Commercial Presence In The Northeast U.S., Expanding Its Service Capabilities And Accelerating Growth In Molecular And Hematology-oncology Testing, Deal Terms Were Not Disclosed

NOVA

Sunnova Appoints Paul Mathews As President And Chief Executive Officer

TECH

Bio-Techne Commences Shipping The Leo System, Powered By Simple Western Technology

TSEM

Tower Semiconductor, Innolight Expand Collaboration Utilizing Newest Silicon Photonics Platform, Now In Production And Ramping To High Volume

JP Morgan analyst Mark Murphy upgrades DocuSign (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DOCU#NASDAQ">DOCU</a>) from Underweight to Neutral and raises the price target from $70 to $75.

Upgrades

Price Target

Analyst Ratings

DOCU

JP Morgan Upgrades DocuSign to Neutral, Raises Price Target to $75

FCEL

Diversified Energy, FuelCell Energy And TESIAC To Form An Acquisition And Development Company Focus On Net-Zero Power From Natural Gas And Captured Coal Mine Methane

<ul>
<li>Launch-HTN met its primary endpoint with lorundrostat 50 mg dose achieving a 16.9 mmHg reduction in systolic blood pressure, and a 9.1 mmHg placebo-adjusted reduction (p-value &lt; 0.0001) assessed by automated office blood pressure at week 6.</li>
<li>Launch-HTN met a predefined endpoint with lorundrostat 50 mg dose achieving a 19.0 mmHg reduction in systolic blood pressure, and an 11.7 mmHg placebo-adjusted reduction (p-value &lt; 0.0001) assessed by automated office blood pressure at end of treatment, week 12.</li>
<li>Advance-HTN met its primary endpoint with lorundrostat 50 mg dose achieving a highly statistically significant 7.9 mmHg placebo-adjusted reduction assessed by 24hr ABPM at end of treatment, week 12.</li>
<li>Lorundrostat demonstrated a favorable safety and tolerability profile in both pivotal trials</li>
</ul>

Biotech

MLYS

Mineralys Therapeutics Announced Topline Data From Its Pivotal Launch-HTN Phase 3 And Pivotal Advance-HTN Phase 2 Trials Of Lorundrostat For Uncontrolled Hypertension Or Resistant Hypertension, Both Trials Met Its Primary Endpoint

ALKT

Alkami Technology Intends To Offer $300M Of Convertible Senior Notes Due 2030 In Private Offering

Dividends

Press Releases

YieldMax™ Launches Option Income Strategy ETF on Alibaba (BABA)

미국 시장은 1월 31일 종료된 <a href="https://www.benzinga.com/25/02/43434471/trumps-tariffs-hit-markets-natural-gas-spikes-mexican-peso-hits-2-year-lows-bitcoin-freefalls-the-outlook-is-unclear-analysts-warn" target="_blank" rel="noopener">강력한 일주일 동안</a> 많은 것들을 소화해야 했다. <a href="https://www.benzinga.com/etfs" target="_blank" rel="noopener">여러 ETF가</a> 연이은 시장 변동성에도 불구하고 두드러진 성과를 보였고, 특히 기술 및 채권 같은 부문에서 주목할 만한 상승세를 보였다. 이번 요약에서 지난주 주요 시장 동향을 자세히 살펴보고 이 기간 동안 상승한 ETF 5종목을 확인해 보자.
이 기사도 읽어보세요: <a href="https://kr.benzinga.com/news/usa/economy/%ED%8A%B8%EB%9F%BC%ED%94%84-%EB%A9%95%EC%8B%9C%EC%BD%94%EC%97%90-%EC%9D%B4%EC%96%B4-%EC%BA%90%EB%82%98%EB%8B%A4-%EA%B4%80%EC%84%B8-30%EC%9D%BC-%EC%9C%A0%EC%98%88-%ED%95%A9%EC%9D%98/" target="_blank" rel="noopener">트럼프, 멕시코에 이어 캐나다 관세 '30일 유예' 합의</a>
Amplify Commodity Trust Breakwave Dry Bulk Shipping ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BDRY#NYSE">BDRY</a>)
<ul>
<li>주간 상승률: 12.26%</li>
<li>특징: 건화물 해운 회사에 순수하게 집중, Breakwave Dry Freight Futures Index 추적</li>
<li>운용수수료: 0.44%</li>
</ul>
Simplify Propel Opportunities ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SURI#NYSE">SURI</a>)
<ul>
<li>주간 상승률: 8.27%</li>
<li>특징: 덜 알려져 있지만 강력한 생명공학, 제약, 건강 기술 및 생명 과학 회사에 대한 노출 및 자본 증대의 기회를 제공</li>
<li>운용수수료: 2.51%</li>
</ul>
Global X Social Media ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOCL#NASDAQ">SOCL</a>)
<ul>
<li>주간 상승률: 3.92%</li>
<li>특징: 소셜 네트워킹, 파일 공유 및 기타 웹 기반 미디어 애플리케이션 포함 소셜미디어 관련 회사에 대한 노출 제공</li>
<li>운용수수료: 0.65%</li>
</ul>
WisdomTree Cybersecurity Fund (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WCBR#NASDAQ">WCBR</a>)
<ul>
<li>주간 상승률: 3.47%</li>
<li>특징: 사이버 보안 기술 관련 회사에 대한 집중 노출 제공</li>
<li>운용수수료: 0.45%</li>
</ul>
YieldMax BABA Option Income Strategy ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BABO#NYSE">BABO</a>)
<ul>
<li>주간 상승률: 7.38%</li>
<li>특징: 액티브 관리 펀드로 알리바바(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BABA#NYSE">BABA</a>)의 콜 옵션을 매도하여 월간 수입을 창출하는 것이 목표</li>
<li>운용수수료: 0.99%</li>
</ul>
<h2 class="wp-block-heading">지난주 시장을 움직인 요인</h2>
1월 31일에 끝난 변동성이 특히 컸던 한 주 동안,<a href="https://www.benzinga.com/25/01/43404983/stocks-trim-deepseek-losses-fed-holds-steady-trump-slaps-25-tariffs-on-canada-mexico-this-week-in-the-markets" target="_blank" rel="noopener"> 강력한 실적 발표가 시장의 구세주 역할을 했다</a>. 티 로우 프라이스(T. Rowe Price)의 트레이더에 따르면, S&amp;P 500 기업 중 약 40%가 수익을 보고했으며, 메타 플랫폼스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>)와 애플(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>)의 강력한 실적이 <a href="https://www.benzinga.com/trading-ideas/movers/25/01/43395813/apple-shares-are-on-the-rise-after-q1-earnings" target="_blank" rel="noopener">주식 반등에 기여했다.</a>
그럼에도 불구하고 S&amp;P 500 지수는 1% 하락한 채로 주를 마감했다. 나스닥 종합지수는 1월 27일 중국 개발업체 딥시크 등장 이후 기술주 매도세에 힘입어 급락했다. 
딥시크의 에너지 효율적인 오픈 소스 AI 모델은 경쟁에 대한 우려를 불러일으켜, 그날 엔비디아 주가가 거의 17% 급락했다. 지수는 1.6% 하락으로 마감했다. 다우존스 산업평균지수는 0.3%의 소폭 상승을 기록하며 3주 연속 상승세를 이어갔다. 
무역 정책도 시장에 영향을 미쳤다. 도널드 트럼프 전 미국 대통령이 2월 1일까지 멕시코와 캐나다에 25%의 관세를 부과하고 중국산 제품에 10%의 관세를 부과할 계획을 재확인했기 때문이다. 
통화정책 관련해서는 연준이 2025년 첫 정책 회의에서 견조한 경제 성장과 탄력적인 노동 시장을 이유로 금리를 4.25%~4.50% 범위로 동결했다.
지난 금요일, 미 상무부의 근원 PCE 인플레이션 보고서에 따르면 12월의 전년 대비 상승률은 2.8%로 3개월 연속 변동이 없었다. 이는 연준의 목표치 2%를 상회하는 수치다. 
한편, 미국 경제는 4분기에 2.3%, 2018년 한 해 동안 2.8% 성장하여, 예상보다 약간 낮았지만 연준의 장기 성장 전망치인 1.8%를 상회했다. 성장의 주된 원동력은 소비와 정부 지출이었다. 
또한 채권 가격 상승으로 국채 수익률이 하락했는데, 이는 부분적으로 딥시크의 파괴적 AI 혁신에 대한 우려 완화로 인한 것이었다.
사진 출처: Shutterstock
Benzinga Pro의 독점 뉴스 및 도구로 수익률을 높이세요.
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

Comments

Tidal Trust II YieldMax BABA Option Income Strategy ETF

뉴스

에 대한 최신 뉴스 Tidal Trust II YieldMax BABA Option Income Strategy ETF (ARCA:BABO)

화요일, 2월 04, 2025

뉴스

파트너 / 기고자

벤징가 글로벌